Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $43.65 million versus the consensus estimate of $49.47 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand
• Teleflex starts global pivotal trial for resorbable magnesium scaffold
• Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT)